Literature DB >> 25362996

High cell density cultivation of a recombinant Escherichia coli strain expressing a 6-O-sulfotransferase for the production of bioengineered heparin.

J Zhang1, M Suflita, C M Fiaschetti, G Li, L Li, F Zhang, J S Dordick, R J Linhardt.   

Abstract

AIMS: One of six heparin biosynthetic enzymes, cloned and expressed in Escherichia coli as a soluble fusion protein, requires large-scale preparation for use in the chemoenzymatic synthesis of heparin, an important anticoagulant drug. METHODS AND
RESULTS: The 6-O-sulfotransferase isoform-3 (6-OST-3) can be conveniently prepared at mg/L levels in the laboratory by culturing E. coli on Luria-Bertani medium in shake flasks and inducing with isopropyl β-D-1-thiogalactopyranoside at an optical density of 0·6-0·8. The production of larger amounts of 6-OST-3 required fed-batch cultivation of E. coli in a stirred tank fermenter on medium containing an inexpensive carbon source, such as glucose or glycerol. The cultivation of E. coli on various carbon sources under different feeding schedules and induction strategies was examined. Conditions were established giving yields (5-20 mg g-cell-dry weight(-1)) of active 6-OST-3 with excellent productivity (2-5 mg l(-1) h(-1)).
CONCLUSIONS: The production of 6-OST-3 in a fed-batch fermentation on an inexpensive carbon source has been demonstrated. SIGNIFICANCE AND IMPACT OF THE STUDY: The ability to scale-up the production of heparin biosynthetic enzymes, such as 6-OST-3, is critical for scaling-up the chemoenzymatic synthesis of heparin. The success of this project may someday lead to a commercially viable bioengineered heparin to replace the animal-sourced anticoagulant product currently on the market.
© 2014 The Society for Applied Microbiology.

Entities:  

Keywords:  biosynthetic enzyme expression; fed-batch fermentation; heparin; high cell density cultivation; optimization of induction; sulfotransferase

Mesh:

Substances:

Year:  2014        PMID: 25362996      PMCID: PMC5292153          DOI: 10.1111/jam.12684

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  13 in total

Review 1.  Order out of chaos: assembly of ligand binding sites in heparan sulfate.

Authors:  Jeffrey D Esko; Scott B Selleck
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

2.  Development of production and purification processes of recombinant fragment of pneumococcal surface protein A in Escherichia coli using different carbon sources and chromatography sequences.

Authors:  Rimenys Junior Carvalho; Joaquin Cabrera-Crespo; Martha Massako Tanizaki; Viviane Maimoni Gonçalves
Journal:  Appl Microbiol Biotechnol       Date:  2011-11-11       Impact factor: 4.813

Review 3.  Protein folding and misfolding.

Authors:  Christopher M Dobson
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

4.  Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events.

Authors:  Marco Guerrini; Daniela Beccati; Zachary Shriver; Annamaria Naggi; Karthik Viswanathan; Antonella Bisio; Ishan Capila; Jonathan C Lansing; Sara Guglieri; Blair Fraser; Ali Al-Hakim; Nur Sibel Gunay; Zhenqing Zhang; Luke Robinson; Lucinda Buhse; Moheb Nasr; Janet Woodcock; Robert Langer; Ganesh Venkataraman; Robert J Linhardt; Benito Casu; Giangiacomo Torri; Ram Sasisekharan
Journal:  Nat Biotechnol       Date:  2008-04-23       Impact factor: 54.908

5.  The N-domain of Escherichia coli phosphoglycerate kinase is a novel fusion partner to express aggregation-prone heterologous proteins.

Authors:  Jong-Am Song; Dae-Sung Lee; Jin-Seung Park; Kyung-Yeon Han; Jeewon Lee
Journal:  Biotechnol Bioeng       Date:  2011-09-09       Impact factor: 4.530

6.  Response surface optimization of the heparosan N-deacetylation in producing bioengineered heparin.

Authors:  Zhenyu Wang; Jennifer Li; Samantha Cheong; Ujjwal Bhaskar; Onishi Akihiro; Fuming Zhang; Jonathan S Dordick; Robert J Linhardt
Journal:  J Biotechnol       Date:  2011-09-10       Impact factor: 3.307

7.  Enzymatic redesigning of biologically active heparan sulfate.

Authors:  Jinghua Chen; Fikri Y Avci; Eva M Muñoz; Lynda M McDowell; Miao Chen; Lars C Pedersen; Lijuan Zhang; Robert J Linhardt; Jian Liu
Journal:  J Biol Chem       Date:  2005-10-31       Impact factor: 5.157

8.  High cell density cultivation of a recombinant E. coli strain expressing a key enzyme in bioengineered heparin production.

Authors:  Odile Francesca Restaino; Ujjwal Bhaskar; Priscilla Paul; Lingyun Li; Mario De Rosa; Jonathan S Dordick; Robert J Linhardt
Journal:  Appl Microbiol Biotechnol       Date:  2013-01-15       Impact factor: 4.813

Review 9.  Lessons learned from the contamination of heparin.

Authors:  Haiying Liu; Zhenqing Zhang; Robert J Linhardt
Journal:  Nat Prod Rep       Date:  2009-01-19       Impact factor: 13.423

10.  Carbon-source-dependent nitrogen regulation in Escherichia coli is mediated through glutamine-dependent GlnB signalling.

Authors:  Mani Maheswaran; Karl Forchhammer
Journal:  Microbiology       Date:  2003-08       Impact factor: 2.777

View more
  4 in total

Review 1.  Advances in the preparation and synthesis of heparin and related products.

Authors:  Sultan N Baytas; Robert J Linhardt
Journal:  Drug Discov Today       Date:  2020-09-16       Impact factor: 7.851

Review 2.  Heparin and related polysaccharides: synthesis using recombinant enzymes and metabolic engineering.

Authors:  Matthew Suflita; Li Fu; Wenqin He; Mattheos Koffas; Robert J Linhardt
Journal:  Appl Microbiol Biotechnol       Date:  2015-07-29       Impact factor: 4.813

Review 3.  Bioengineered heparins and heparan sulfates.

Authors:  Li Fu; Matthew Suflita; Robert J Linhardt
Journal:  Adv Drug Deliv Rev       Date:  2015-11-10       Impact factor: 15.470

Review 4.  Engineered heparins as new anticoagulant drugs.

Authors:  Deepika Vaidyanathan; Asher Williams; Jonathan S Dordick; Mattheos A G Koffas; Robert J Linhardt
Journal:  Bioeng Transl Med       Date:  2016-11-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.